Free Trial

Amedisys (AMED) Competitors

Amedisys logo
$97.48 -0.03 (-0.03%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$97.49 +0.01 (+0.01%)
As of 07/16/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELAN

Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN).

Amedisys vs. Its Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Amedisys has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

In the previous week, DaVita had 8 more articles in the media than Amedisys. MarketBeat recorded 11 mentions for DaVita and 3 mentions for Amedisys. Amedisys' average media sentiment score of 1.22 beat DaVita's score of 1.09 indicating that Amedisys is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amedisys
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DaVita
8 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amedisys presently has a consensus price target of $100.75, indicating a potential upside of 3.35%. DaVita has a consensus price target of $164.50, indicating a potential upside of 17.31%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than Amedisys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
DaVita
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 2.1% of Amedisys shares are owned by insiders. Comparatively, 2.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.

Company Net Margins Return on Equity Return on Assets
Amedisys3.79% 12.52% 7.01%
DaVita 6.63%176.11%4.66%

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$2.35B1.36$43.23M$2.7135.97
DaVita$12.82B0.83$936.34M$10.0913.90

Summary

DaVita beats Amedisys on 8 of the 15 factors compared between the two stocks.

Get Amedisys News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMED vs. The Competition

MetricAmedisysMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.20B$3.74B$5.51B$9.31B
Dividend YieldN/A1.36%4.25%4.10%
P/E Ratio35.9734.9928.1719.69
Price / Sales1.3698.31438.93100.42
Price / Cash15.6522.5035.5357.53
Price / Book2.714.278.225.67
Net Income$43.23M$189.47M$3.23B$257.51M
7 Day Performance-0.19%-2.25%-0.59%-0.16%
1 Month Performance-0.03%-5.98%6.65%9.89%
1 Year Performance-0.28%-4.59%26.87%15.08%

Amedisys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.8676 of 5 stars
$97.48
0.0%
$100.75
+3.4%
-0.3%$3.20B$2.35B35.9719,000News Coverage
Positive News
Upcoming Earnings
DVA
DaVita
4.4192 of 5 stars
$143.43
+0.6%
$164.50
+14.7%
+1.8%$10.83B$12.82B14.2176,000Positive News
CHE
Chemed
4.9806 of 5 stars
$464.42
+1.0%
$645.00
+38.9%
-16.2%$6.79B$2.49B22.6215,695
CRVL
CorVel
1.0021 of 5 stars
$97.99
+0.2%
N/A+1.2%$5.04B$895.59M53.355,075Positive News
MD
Pediatrix Medical Group
2.9717 of 5 stars
$13.15
+0.2%
$16.67
+26.8%
+68.1%$1.13B$1.98B-13.014,305Positive News
AMN
AMN Healthcare Services
4.2448 of 5 stars
$20.72
-2.1%
$32.08
+54.8%
-65.0%$793.27M$2.85B-4.792,968Gap Up
CCRN
Cross Country Healthcare
3.8577 of 5 stars
$12.08
+0.1%
$17.93
+48.4%
-20.9%$396.02M$1.26B-22.798,205News Coverage
LH
Labcorp
4.6134 of 5 stars
$249.77
+0.1%
$276.38
+10.7%
+13.6%$20.91B$13.01B28.8770,000Upcoming Earnings
Dividend Announcement
DGX
Quest Diagnostics
4.9447 of 5 stars
$168.34
+0.1%
$185.73
+10.3%
+12.4%$18.79B$9.87B21.2856,000Upcoming Earnings
EHC
Encompass Health
4.9283 of 5 stars
$119.64
+1.0%
$131.50
+9.9%
+26.2%$12.06B$5.37B24.7240,000
ELAN
Elanco Animal Health
1.5114 of 5 stars
$14.88
-0.2%
$15.33
+3.1%
+9.5%$7.39B$4.44B20.109,000

Related Companies and Tools


This page (NASDAQ:AMED) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners